SCHEMBL6941298

SCHEMBL6941298

CC(C)(C)OC(=O)N(C(=O)OC(C)(C)C)c1ccc(CN2C(=O)c3ccccc3C2=O)c(Cl)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.40
MAPT P10636 3/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
TYR P14679 1/20 0.38
HTT P42858 2/20 0.38
MEN1 O00255 1/20 0.38
GAA P10253 1/20 0.38
ALOX15 P16050 1/20 0.38
KMT2A Q03164 1/20 0.38
HSD17B10 Q99714 1/20 0.38
LMNA P02545 1/20 0.38
TP53 P04637 1/20 0.38
GRM5 P41594 7/20 0.38
HPGD P15428 1/20 0.38
POLB P06746 1/20 0.38
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7479630 0.78 ALDH1A1 (0.40) ALDH1A1MAPTTSHRMAPK1TYR
SCHEMBL5673919 0.77 MT-CO2 (0.38) ALDH1A1MAPTHTTMEN1KMT2A
SCHEMBL11820042 0.74 KMT2A (0.45) ALDH1A1MAPTTSHRMAPK1HTT
SCHEMBL15492070 0.72 HPGD (0.48) ALDH1A1MAPTTSHRMAPK1HTT
SCHEMBL5673951 0.72 ALDH1A1 (0.33) ALDH1A1MAPTTSHRHTTMEN1
SCHEMBL7654082 0.72 MEN1 (0.56) MAPTTSHRMAPK1MEN1KMT2A
SCHEMBL21996116 0.71 GRM5 (0.42) ALDH1A1MAPTTSHRMAPK1HTT
SCHEMBL10384459 0.71 ALDH1A1 (0.60) ALDH1A1MAPTHTTMEN1KMT2A
SCHEMBL11081773 0.71 MAPT (0.58) ALDH1A1MAPTTSHRMAPK1TYR
SCHEMBL21998270 0.71 L3MBTL1 (0.48) MEN1GAAKMT2AHPGDPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1080069-B1 ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE FUJISAWA PHARMACEUTICAL CO (JP) 2003-03-19 EP disclosed
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-12-19 US disclosed
US-6384080-B1 TREATMENT AND/OR PREVENTION OF CERTAIN CARDIOVASCULAR DISORDERS, UROGENITAL DISORDERS, RESPIRATORY SYSTEM DISORDERS, DISORDERS OF GUT MOTILITY, SEXUAL DISORDERS, DIABETIC COMPLICATIONS, URTICARIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-05-07 US disclosed
EP-1080069-A1 ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-03-07 EP disclosed
WO-1999054284-A1 ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase PDE3A, PDE2A, PDE5A ALDH1A1 253/4885MAPT 4706/4885TSHR 3320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.